Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of TAK-385 versus leuprorelin for uterine fibroids
jRCT2080223074Phase 3
- Sponsor
- Takeda
- Start
- Jan 2016
- Modality
- Small Molecules, Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Fibromyoma (LM) comparing TAK-385 arm with Leuprorelin arm (2 arms).
02
Drugs
tissue-plasminogen activatorleuprolide
03
Conditions
Fibromyoma (LM)
Beyond the preview
Go deeper on jRCT2080223074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223074.